Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov 17;73(20):1616-23.
doi: 10.1212/WNL.0b013e3181c1e44f. Epub 2009 Nov 4.

Impact of multiple sclerosis relapses on progression diminishes with time

Collaborators, Affiliations

Impact of multiple sclerosis relapses on progression diminishes with time

H Tremlett et al. Neurology. .

Abstract

Objective: The relationship between relapses and long-term disability in multiple sclerosis (MS) remains to be fully elucidated. Current literature is conflicting and focused on early relapses. We investigated the effects of relapses at different stages on disability progression.

Methods: We conducted a retrospective review of 2,477 patients with definite relapsing-onset MS followed until July 2003 in British Columbia, Canada. Time-dependent Cox proportional hazards models examined the effect of relapses at different time periods (0-5; >5-10; >10 years postonset) on time to cane (Expanded Disability Status Scale [EDSS]) and secondary progressive MS (SPMS). Findings were derived from hazard ratios with 95% confidence intervals (CIs), adjusted for sex, onset age, and symptoms.

Results: Mean follow-up was 20.6 years; 11,722 postonset relapses were recorded. An early relapse (within 5 years postonset) was associated with an increased hazard in disease progression over the short term, by 48%; 95% CI 37%-60% for EDSS 6 and 29%; 95% CI 20%-38% for SPMS. However, this substantially lessened to 10%; 95% CI 4%-16% (EDSS 6) and 2%; 95% CI -2%-7% (SPMS) after 10 years postonset. The impact of later relapses (>5-10 years postonset) also lessened over time. Effects were modulated by age, impact being greatest in younger (<25 years at onset) and least in older (>or=35 years) patients where relapses beyond 5-years postonset typically failed to reach significance. Relapses during SPMS had no measurable impact on time to EDSS 6 from SPMS.

Conclusion: Relapses within the first 5 years of disease impacted on disease progression over the short term. However, the long-term impact was minimal, either for early or later relapses. Long-term disease progression was least affected by relapses in patients with an extended disease duration (>10 years) or already in the secondary progressive phase.

PubMed Disclaimer

Figures

None
Figure 1 Effect of early relapses on disease progression Kaplan-Meier curves: annualized relapse rate in the first 5 years and time to Expanded Disability Status Scale (EDSS) 6 (A); Kaplan-Meier curves: annualized relapse rate in the first 5 years and time to secondary progressive multiple sclerosis (SPMS) (B).
None
Figure 2 Impact of a relapse on the hazard of reaching EDSS 6 at different time points Hazard ratios were calculated from Cox regression analysis, controlling for sex, age at onset, and onset symptoms. The percentage change in hazard is relative to the risk of reaching EDSS 6 under the same conditions, but under the scenario of no relapse. *Censored patients = those who did not reach sustained EDSS 6 by the study end. MS = multiple sclerosis; EDSS = Expanded Disability Status Scale; CI = confidence interval.
None
Figure 3 Impact of a relapse on the hazard of reaching SPMS at different time points Hazard ratios were calculated from Cox regression analysis, controlling for sex, age at onset, and onset symptoms. *Censored patients = those who did not reach SPMS by the study end. MS = multiple sclerosis; SPMS = secondary progressive multiple sclerosis; CI = confidence interval.

Comment in

Similar articles

Cited by

References

    1. Compston A, Coles AJ. Multiple sclerosis. Lancet 2002;359:1221–1231. - PubMed
    1. Waxman SG. Demyelinating diseases: new pathological insights, new therapeutic targets. N Engl J Med 1998;338:323–325. - PubMed
    1. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98–108. - PubMed
    1. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528–1532. - PubMed
    1. Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol 2008;255:280–287. - PubMed

Publication types